Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

被引:0
|
作者
M J L Ligtenberg
F B L Hogervorst
H W Willems
P J W Arts
G Brink
S Hageman
E A J Bosgoed
E Van der Looij
M A Rookus
P Devilee
E M A W Vos
G Wigbout
P M Struycken
F H Menko
E J Th Rutgers
E H Hoefsloot
E C M Mariman
H G Brunner
L J Van’t Veer
机构
[1] University Hospital Nijmegen,Department of Human Genetics
[2] University Hospital Nijmegen,Department of Pathology
[3] The Netherlands Cancer Institute,Department of Pathology and The Family Cancer Clinic
[4] Plesmanlaan 121,Department of Epidemiology
[5] The Netherlands Cancer Institute,Department of Human Genetics and Department of Pathology
[6] Plesmanlaan 121,Department of Clinical Genetics
[7] University of Leiden,undefined
[8] Family Cancer Clinic,undefined
[9] University Hospital Vrije Universiteit,undefined
来源
British Journal of Cancer | 1999年 / 79卷
关键词
breast cancer; ovarian cancer; bilateral breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations (25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79 families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.
引用
收藏
页码:1475 / 1478
页数:3
相关论文
共 50 条
  • [21] BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland
    Ratajska, Magdalena
    Brozek, Izabela
    Senkus-Konefka, Elzbieta
    Jassem, Jacek
    Stepnowska, Magdalena
    Palomba, Grazia
    Pisano, Marina
    Casula, Milena
    Palmier, Giuseppe
    Borg, Ake
    Limon, Janusz
    ONCOLOGY REPORTS, 2008, 19 (01) : 263 - 268
  • [22] Frequency of BRCA1 and BRCA2 Mutations in a Clinic-Based Series of Breast and Ovarian Cancer Families
    Vaziri, Susan A. J.
    Krumroy, Lisa M.
    Rostai, Majid
    Casey, Graham
    HUMAN MUTATION, 2001, 17 (01) : 74
  • [23] Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
    Simone Maistro
    Natalia Teixeira
    Giselly Encinas
    Maria Lucia Hirata Katayama
    Vivian Dionisio Tavares Niewiadonski
    Larissa Garcia Cabral
    Roberto Marques Ribeiro
    Nelson Gaburo Junior
    Ana Carolina Ribeiro Chaves de Gouvêa
    Dirce Maria Carraro
    Ester Cerdeira Sabino
    Maria del Pilar Estevez Diz
    Roger Chammas
    Geertruida Hendrika de Bock
    Maria Aparecida Azevedo Koike Folgueira
    BMC Cancer, 16
  • [24] Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
    Maistro, Simone
    Teixeira, Natalia
    Encinas, Giselly
    Hirata Katayama, Maria Lucia
    Tavares Niewiadonski, Vivian Dionisio
    Cabral, Larissa Garcia
    Ribeiro, Roberto Marques
    Gaburo Junior, Nelson
    Ribeiro Chaves de Gouvea, Ana Carolina
    Carraro, Dirce Maria
    Sabino, Ester Cerdeira
    Estevez Diz, Maria del Pilar
    Chammas, Roger
    de Bock, Geertruida Hendrika
    Azevedo Koike Folgueira, Maria Aparecida
    BMC CANCER, 2016, 16
  • [25] BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants
    Delgado, L.
    Fernandez, G.
    Grotiuz, G.
    Cataldi, S.
    Gonzalez, A.
    LLuveras, N.
    Heguaburu, M.
    Fresco, R.
    Lens, D.
    Sabini, G.
    Muse, I. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (01) : 211 - 218
  • [26] Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients
    Jae Myoung Noh
    Doo Ho Choi
    Seok Jin Nam
    Jeong Eon Lee
    Jong Won Kim
    Sung-Won Kim
    Eunyoung Kang
    Min Hyuk Lee
    Sei Hyun Ahn
    Ku Sang Kim
    Sue K. Park
    Bruce G. Haffty
    Breast Cancer Research and Treatment, 2012, 131 : 217 - 222
  • [27] Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations
    Kim, Daniel H.
    Crawford, Beth
    Ziegler, John
    Beattie, Mary S.
    FAMILIAL CANCER, 2009, 8 (02) : 153 - 158
  • [28] Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients
    Noh, Jae Myoung
    Choi, Doo Ho
    Nam, Seok Jin
    Lee, Jeong Eon
    Kim, Jong Won
    Kim, Sung-Won
    Kang, Eunyoung
    Lee, Min Hyuk
    Ahn, Sei Hyun
    Kim, Ku Sang
    Park, Sue K.
    Haffty, Bruce G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (01) : 217 - 222
  • [29] A family with three germline mutations in BRCA1 and BRCA2
    Liede, A
    Metcalfe, K
    Offit, K
    Brown, K
    Miller, S
    Narod, SA
    Moslehi, R
    CLINICAL GENETICS, 1998, 54 (03) : 215 - 218
  • [30] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453